Integra LifeSciences to Present at Four Investor Conferences in November

/ Source: GlobeNewswire

PLAINSBORO, N.J., Oct. 28, 2010 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) announced today that it will present at four conferences next month.

Mr. John B. Henneman, III, Executive Vice President and Chief Financial Officer of Integra, will present at the following two conferences:

  • Wednesday, November 3rd, 2010 at 10:15 AM ET at the Oppenheimer 21st Annual Healthcare Conference at the Waldorf Astoria in New York City. A live webcast of the presentation will be available via a link on the Investor Relations page of our website at .
  • Wednesday, November 17th, 2010 at 8:05 AM PT, at the Citi Small and Mid Cap Conference at the Four Seasons Hotel in Las Vegas, NV. There will be no webcast for this conference.

On Tuesday, November 16th, 2010 at 9:30 AM ET, Mr. Stuart Essig, Chief Executive Officer of Integra, will present at the Stephens Fall Investment Conference at The New York Palace Hotel in New York City.

On Wednesday, November 17th, 2010 at 10:00 AM ET, Ms. Angela Steinway, Head of Investor Relations, and Mr. Brian Larkin, President, Global Spine & Orthobiologics and Head of Strategic Development will present at the Lazard Capital Markets 7th Annual Healthcare Conference at The St. Regis Hotel in New York City. There will be no webcast for the above two conferences.

Integra LifeSciences, a world leader in medical devices, is dedicated to limiting uncertainty for surgeons, so they can concentrate on providing the best patient care. Integra offers innovative solutions in orthopedics, neurosurgery, spine, reconstructive and general surgery. For more information, please visit

Statements made at the upcoming conferences may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ from predicted results. Forward-looking factors that may be discussed include, but are not limited to, future financial performance, new product development, governmental approvals, market potential and resulting sales as well as potential therapeutic applications, and additional acquisitions. These risks and uncertainties include market conditions and other factors beyond the Company's control and the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in item IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2009 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results. These forward-looking statements are made only as the date thereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.

IART-G

CONTACT: Integra LifeSciences Holdings Corporation John B. Henneman, III, Executive Vice President, Finance and Administration and Chief Financial Officer (609) 275-0500 jack.henneman@integralife.com Investor Relations: Angela Steinway (609) 936-2268 angela.steinway@integralife.com